Market News
Fish Skin Disease Market Recent Developments
New product launches
- In September 2021, Sonnet BioTherapeutics, a clinical stage biotechnology company entered into a license option agreement with Strides Pharma Science Limited, a pharmaceutical company to develop SON-1010, an interleukin-12 (IL-12) targeted immunotherapy, for the treatment of ichthyosis. This agreement allows Sonnet to evaluate SON-1010 as a potential new therapy for improved treatment of ichthyosis.
- In April 2022, Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TMB-001, a topical isotretinoin formulated using the company’s patented IPEG™ delivery system, for the treatment of X-linked recessive ichthyosis (XRI) and autosomal recessive congenital ichthyosis lamellar ichthyosis (ARCI-LI).
- In January 2022, AbbVie Inc, a specialty biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended.
- In May 2020, Krystal Biotech, the leader in redosable gene therapy, announced interim results for a first-in-human Phase 1/2 placebo controlled clinical trial evaluating topical administration of KB105 in patients with autosomal recessive congenital ichthyosis (ARCI) being presented at the Society for Investigative Dermatology (SID) annual meeting.
Acquisition and partnerships:
- On August 22 2023, LEO Pharma, a pharmaceutical company, announced that it had signed an agreement to acquire Timber Pharmaceuticals.
U.S.: 
U.K. : 
India : 
